Drug Compounding Can't Be Justified By Price, FDA Says

Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.

Pharmacistswithmortatandpestle_1200x675

A physician can't use a lower price to justify ordering a compounded version of a drug that is already available on the market.

FDA wants a legitimate clinical change made in order to justify making the alternative to an approved product. But the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet